Case-Control Study of Inflammatory Breast Cancer in North Africa
- Inflammatory breast cancer (IBC) is a rare, poorly understood and particularly aggressive form of breast cancer.
- Three characteristics of IBC tumors - their rapid progression, their extensive formation of new blood vessels, and the fact that these characteristics are present from the inception of the tumor - make it an ideal model for studying factors associated with tumor aggressiveness.
- This study is a collaboration among several institutions in the United States and North Africa that have extensive epidemiological experience and experience with IBC.
- To understand what causes certain types of breast conditions, including IBC.
- Women 18 years of age and older with IBC and non-IBC and healthy women volunteers are eligible. Women who have had a previous diagnosis of any kind of breast cancer are excluded.
- Participants complete a questionnaire providing information about their background, including medical and reproductive history, family health history and lifestyle habits and undergo the following additional procedures:
- Height, weight, hip and chest measurements.
- Saliva sample collection to measure biological factors that may be related to breast conditions.
- Breast examination and, if permission is given, photographs of affected breast.
- Analysis of biopsied tissue for genetic and biochemical factors.
Inflammatory Breast Cancer
|Official Title:||A Case-Control Study of Inflammatory Breast Cancer in North Africa|
|Study Start Date:||November 2008|
Inflammatory breast cancer (IBC) is a rare, poorly understood and particularly aggressive form of breast cancer characterized by diffuse erythema and edema/peau d'orange of the breast. The proposed case-control study of risk factors for IBC will include approximately 400 IBC cases accrued over a two-year period in centers in four countries in North Africa (the major cancer center and selected private clinicians in Tunisia, the major cancer center in Egypt, 2 cancer centers in Algeria, and 2 cancer centers in Morocco). Two control groups will be included: 1) 400 non-IBC breast cancer cases and; 2) 400 visitor controls (excluding those with breast, ovarian, endometrial, and nasopharyngeal cancers) in the study hospitals. The study will involve the administration of a questionnaire, anthropometric measurements, and saliva collection for all study subjects. In addition, digital photographs of the breasts will be collected for IBC cases, and a clinical examination form and paraffin-embedded tumor tissue will be collected for IBC cases and non-IOBC breast cancer controls. The study will be conducted as a consortium, with form development and translation coordinated at the National Cancer Institute (USA). A review of study procedures will be done after the first three months of data collection. The National Cancer Institute (NCI)-Division of Cancer Epidemiology and Genetics (DCEG), NCI-Office of International Affairs (OIA), University of Michigan, and International Breast Cancer Research Foundation (IBCRF) will provide funding for the project.
|Contact: Catherine Schairer, Ph.D.||(301) email@example.com|
|Annaba Cancer Center||Recruiting|
|Blida Cancer Center||Recruiting|
|National Cancer Institute-Cairo||Recruiting|
|Oncology Center Ibn Rochd||Recruiting|
|National Institute of Oncology||Recruiting|
|Principal Investigator:||Catherine Schairer, Ph.D.||National Cancer Institute (NCI)|